美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Polaryx Therapeutics, Inc.

8.91

-7.0900-44.31%

盤後：8.68-0.2300-2.58%17:07 EST

成交量：18.60萬

成交額：165.89萬

市值：4.22億

市盈率：- -

高：17.20

開：17.20

低：7.35

收：16.00

52周最高：48.91

52周最低：7.35

股本：4,734.33萬

流通股本：4,734.33萬

量比：6.36

換手率：0.39%

股息：- -

股息率：- -

每股收益(LYR):-0.8876

淨資產收益率：--

總資產收益率：--

市淨率：79.58

市盈率(LYR):-10.04

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

Polaryx Therapeutics, Inc.

交易所：

NASDAQ

成立時間：

2014

員工人數：

11

公司地址：

South Tower,140 E Ridgewood Avenue,Suite 415,Paramus,New Jersey,United States

官網：

http://www.polaryx.com

郵編：

07652

電話：

傳真：

- -

簡介：

Polaryx Therapeutics, Inc.最初於2014年8月22日在懷俄明州註冊成立。2025年10月24日，公司完成了重新註冊過程，轉為內華達州公司。Polaryx是一家臨床階段的生物技術公司，致力於發現、開發和商業化針對罕見兒童溶酶體儲積病（LSDs）的創新療法。公司採用多模式治療方法，結合小分子藥物療法和基因療法，旨在解決這些疾病的遺傳原因和下游影響。其領先的藥物候選產品PLX-200，針對多種LSDs，並已進入臨床試驗階段。Polaryx的藥物開發戰略以提供安全、有效、以患者為中心的治療方案為核心，旨在滿足這些疾病尚未解決的重大需求。

董事

名稱

職位

Alex Yang

Chair of the Board and Chief Executive Officer

Charles Ryan

Independent Director

Francis A. Braun

Independent Director

G. Michael Landis

Chief Financial Officer and Director

Mitchel Berger

Independent Director

股東

名稱

職位

Alex Yang

Chair of the Board and Chief Executive Officer

G. Michael Landis

Chief Financial Officer and Director

Andrew O

Chief Investment Officer

Lisa L. Bollinger

Chief Medical Officer

Minsu Kang

Director of Regulatory and Clinical Affairs

Shrijay Vijayan

Chief Scientific and Business Development Officer

Wuxin Zhu

Chief Chemistry, Manufacturing and Controls Officer

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hant/stock/PLYX/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PLYX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLYX\",,,,,undefined,":{"symbol":"PLYX","market":"US","secType":"STK","nameCN":"Polaryx Therapeutics, Inc.","latestPrice":8.91,"timestamp":1770411600000,"preClose":16,"halted":0,"volume":186027,"hourTrading":{"tag":"盘后","latestPrice":8.68,"preClose":8.91,"latestTime":"17:07 EST","volume":3493,"amount":29974.641578,"timestamp":1770415631541,"change":-0.23,"changeRate":-0.025814,"amplitude":0.08193},"delay":0,"changeRate":-0.443125,"floatShares":47343297,"shares":47343297,"eps":0,"marketStatus":"盤後交易","change":-7.09,"latestTime":"02-06 17:08:38 EST","open":17.2,"high":17.2,"low":7.35,"amount":1658884.6108799998,"amplitude":0.615625,"askPrice":8.7,"askSize":100,"bidPrice":8,"bidSize":149,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1770426000000},"marketStatusCode":4,"adr":0,"listingDate":1769749200000,"exchange":"NASDAQ","adjPreClose":16,"preHourTrading":{"tag":"盘前","latestPrice":17,"preClose":16.25,"latestTime":"09:28 EST","volume":393,"amount":6644.939498999999,"timestamp":1770388082496,"change":0.75,"changeRate":0.046154,"amplitude":0.159385},"postHourTrading":{"tag":"盘后","latestPrice":8.68,"preClose":8.91,"latestTime":"17:07 EST","volume":3493,"amount":29974.641578,"timestamp":1770415631541,"change":-0.23,"changeRate":-0.025814,"amplitude":0.08193},"volumeRatio":6.355715},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLYX\",,,,,undefined,":{"symbol":"PLYX","floatShares":47343297,"roa":"--","roe":"--","lyrEps":-0.887585,"volumeRatio":6.355715,"shares":47343297,"dividePrice":0,"high":17.2,"amplitude":0.615625,"preClose":16,"low":7.35,"week52Low":7.35,"pbRate":"79.58","week52High":48.91,"institutionHeld":0,"latestPrice":8.91,"committee":0.196787,"eps":0,"divideRate":0,"volume":186027,"delay":0,"ttmEps":0,"open":17.2,"prevYearClose":45,"prevWeekClose":45,"prevMonthClose":45,"prevQuarterClose":45},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PLYX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PLYX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PLYX\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PLYX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PLYX","date":"2026-02-05","current":-129.699766,"percent":0.25,"low":-201.755192,"twenty":-144.110851,"median":-126.529328,"eighty":-58.797227,"high":-58.797227,"avg":-115.115748,"sd":53.278341,"marketCap":1065224182},"quantilePoints":[{"date":"2026-01-30","current":-58.797227,"twenty":-58.797227,"median":-58.797227,"eighty":-58.797227,"marketCap":482901629},{"date":"2026-02-05","current":-129.699766,"twenty":-144.110851,"median":-126.529328,"eighty":-58.797227,"marketCap":1065224182}],"updateTime":1770415498282},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":414729746,"yearFounded":2014,"employeeNum":11,"address":"South Tower,140 E Ridgewood Avenue,Suite 415,Paramus,New Jersey,United States","zipCode":"07652","officePhone":"201 940 7236"},"stockCompanyDetail":{"websiteUrl":"http://www.polaryx.com","stockEarnings":[{"period":"1week","weight":-0.6444},{"period":"ytd","weight":-0.6444}],"compareEarnings":[{"period":"1week","weight":-0.0237},{"period":"1month","weight":-0.0205},{"period":"3month","weight":0.0099},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1215},{"period":"ytd","weight":-0.0063}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Polaryx Therapeutics, Inc.最初於2014年8月22日在懷俄明州註冊成立。2025年10月24日，公司完成了重新註冊過程，轉為內華達州公司。Polaryx是一家臨床階段的生物技術公司，致力於發現、開發和商業化針對罕見兒童溶酶體儲積病（LSDs）的創新療法。公司採用多模式治療方法，結合小分子藥物療法和基因療法，旨在解決這些疾病的遺傳原因和下游影響。其領先的藥物候選產品PLX-200，針對多種LSDs，並已進入臨床試驗階段。Polaryx的藥物開發戰略以提供安全、有效、以患者為中心的治療方案為核心，旨在滿足這些疾病尚未解決的重大需求。","exchange":"NASDAQ","name":"Polaryx Therapeutics, Inc.","nameEN":"Polaryx Therapeutics, Inc."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"PLYX\",market:\"US\",,,undefined,":{"directors":[{"name":"Alex Yang","position":"Chair of the Board and Chief Executive Officer"},{"name":"Charles Ryan","position":"Independent Director"},{"name":"Francis A. Braun","position":"Independent Director"},{"name":"G. Michael Landis","position":"Chief Financial Officer and Director"},{"name":"Mitchel Berger","position":"Independent Director"}],"executives":[{"name":"Alex Yang","position":"Chair of the Board and Chief Executive Officer"},{"name":"G. Michael Landis","position":"Chief Financial Officer and Director"},{"name":"Andrew O","position":"Chief Investment Officer"},{"name":"Lisa L. Bollinger","position":"Chief Medical Officer"},{"name":"Minsu Kang","position":"Director of Regulatory and Clinical Affairs"},{"name":"Shrijay Vijayan","position":"Chief Scientific and Business Development Officer"},{"name":"Wuxin Zhu","position":"Chief Chemistry, Manufacturing and Controls Officer"}]}}}